-
Mashup Score: 0Joseph Alvarnas, MD, Discusses New CMS Drug Pricing Models, Impact for Blood Diseases - 1 year(s) ago
CMS in February 2023 announced 3 new models for testing by the Center for Medicare & Medicaid Innovation—all of which “aim to lower the cost of drugs, promote accessibility to life-changing drug therapies, and improve quality of care.”
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Under the transaction, TPG, an asset management firm, will acquire a majority interest in OneOncology and AmerisourceBergen will have a minority interest; OneOncology physician leaders and practices will retain minority interests as well.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
TPG, AmerisourceBergen Acquire @OneOncology in Deal Valued at $2.1 Billion https://t.co/1MSX8fQlQs via @AJMC
-
-
Mashup Score: 0Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection - 1 year(s) ago
This combination is among the many cancer vaccine collaborations being pursued.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Moderna and Merck’s Cancer Vaccine Cuts Risk of Recurrence or Death 44% in Late-Stage, High-Risk Melanoma After Resection $MRK @AACR https://t.co/tnpwkAgO5n via @AJMC
-
-
Mashup Score: 0NCCN Session Offers Considerations for Frontline, Second-line Treatment Choices in CLL - 1 year(s) ago
An April 1 session at the 2023 National Comprehensive Cancer Network (NCCN) on updates in CLL/SLL featured results on the ALPINE study, which led to the January 2023 approval of zanubrutinib in the frontline setting.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@NCCN Session Offers Considerations for Frontline, Second-line Treatment Choices in #CLL https://t.co/eMS0Z8fYyH via @AJMC
-
-
Mashup Score: 0Delivery Matters: In Early Studies, DPX Technology Allows Vaccines to Persist When Cancer Pushes Back - 1 year(s) ago
Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Delivery Matters: In Early Studies, DPX Technology Allows Vaccines to Persist When Cancer Pushes Back #IMV #DLBCL #ovarian https://t.co/ZhmHMlqdQO via @AJMC
-
-
Mashup Score: 2'Live free and die'? The sad state of U.S. life expectancy - 1 year(s) ago
A decade after a landmark report on Americans’ shorter lives, the problem has only gotten worse. Unlike other wealthy nations, U.S. life expectancy has not bounced back from the pandemic.
Source: NPRCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
'Live free and die'? The sad state of U.S. life expectancy https://t.co/wHJNnFESzz
-
-
Mashup Score: 0Delivery Matters: In Early Studies, DPX Technology Allows Vaccines to Persist When Cancer Pushes Back - 1 year(s) ago
Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Delivery Matters: In Early Studies, DPX Technology Allows Vaccines to Persist When Cancer Pushes Back #IMV https://t.co/ZhmHMlqdQO via @AJMC
-
-
Mashup Score: 0
A panel at the Community Oncology Alliance (COA) 2023 Community Oncology Conference highlights the evolution of taking on risk, developing stratification models, and collaborating to learn from fellow providers.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Community Oncology Offers Nimbleness for Pivot to Value-Based Care #COA2023 @oncologyCOA https://t.co/pgSuuLrcpx via @AJMC
-
-
Mashup Score: 0Could This Be the Year for PBM Reform? COA Panel Weighs in - 1 year(s) ago
Capitol Hill experts taking part in the Community Oncology Alliance’s (COA) Community Oncology Conference said Friday that bipartisan awareness of pharmacy benefit manager (PBM) practices has reached a point that they believe Congress may finally act, if only to require greater transparency.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Could This Be the Year for #PBM Reform? #COA2023 Panel Weighs in @oncologyCOA @TheUSONetwork @ACCCBuzz https://t.co/0XxhldExXI via @AJMC
-
-
Mashup Score: 0As Decision Time on EOM Nears, Lots of Questions From COA Panel - 1 year(s) ago
A chief concern among those considering the upcoming alternative payment model in oncology, the Enhancing Oncology Model (EOM): Practices will have to take on downside risk immediately.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
As Decision Time on #EOM Nears, Lots of Questions From #COA2023 Panel https://t.co/VbLSwRcjVI via @AJMC
-
Joseph Alvarnas, MD, Discusses New CMS Drug Pricing Models, Impact for Blood Diseases @cityofhope https://t.co/2Gb2MNoIJd via @AJMC